keyword
MENU ▼
Read by QxMD icon Read
search

Hemostatic agent

keyword
https://www.readbyqxmd.com/read/29774181/embolization-with-ethylene-vinyl-alcohol-copolymer-onyx-%C3%A2-for-peripheral-hemostatic-and-non-hemostatic-applications-a-feasibility-and-safety-study
#1
Romaric Né, Olivier Chevallier, Nicolas Falvo, Olivier Facy, Pierre-Emmanuel Berthod, Christophe Galland, Sophie Gehin, Marco Midulla, Romaric Loffroy
Background: Onyx® is a liquid embolic agent, which is approved for the treatment of cerebral vascular lesions but still rarely used in peripheral interventional radiology. The goal of this study is to report the feasibility and safety of embolization with Onyx® for peripheral hemostatic and non-hemostatic endovascular procedures. Methods: Retrospective study of all consecutive patients who underwent visceral or peripheral embolization with Onyx® for hemostatic or non-hemostatic purpose in our department between May 2014 and November 2016...
April 2018: Quantitative Imaging in Medicine and Surgery
https://www.readbyqxmd.com/read/29770717/treatment-patterns-and-health-care-resource-utilization-and-costs-in-heavy-menstrual-bleeding-a-japanese-claims-database-analysis
#2
Sayako Akiyama, Erika Tanaka, Olivier Cristeau, Yoshie Onishi, Yutaka Osuga
AIMS: Heavy menstrual bleeding (HMB) is a highly prevalent condition characterized by excessive menstrual blood loss and cramping that interferes with activities of daily life. The aim of our study was to investigate treatment patterns in HMB in Japan, and to assess healthcare resource utilization and costs among women newly diagnosed with the condition. MATERIALS AND METHODS: We retrospectively analysed health insurance data available in the Japan Medical Data Center (JMDC) database on women aged 18-49 years who were newly diagnosed with primary or secondary HMB...
May 17, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29769259/novel-therapeutics-for-hemophilia-and-other-bleeding-disorders
#3
Michael U Callaghan, Robert Sidonio, Steven W Pipe
Hemophilia and von Willebrand disease are the most common congenital bleeding disorders. Treatment for these disorders has focused on replacement of the missing coagulation factor to prevent or treat bleeding. New technologies and insights into hemostasis have driven the development of many promising new therapies for hemophilia and von Willebrand disease. Emerging bypass agents including zymogen-like factor IXa and Xa molecules are in development and a bispecific antibody, emicizumab, demonstrated efficacy in a phase III trial in people with hemophilia A and inhibitors...
May 16, 2018: Blood
https://www.readbyqxmd.com/read/29764497/activated-prothrombin-complex-concentrate-to-reverse-the-factor-xa-inhibitor-apixaban-effect-before-emergency-surgery-a-case-series
#4
Nina Haagenrud Schultz, Runar Lundblad, Pål Andre Holme
BACKGROUND: The lack of an antidote against factor Xa inhibitors in case of major bleeding or need for urgent surgery is a concern to clinicians. Guidelines on managing major bleeding in patients under anticoagulation with a factor Xa inhibitor suggest several hemostatic agents to reverse the effect, but there is no consensus regarding the choice of drug or appropriate dose. The ability of prothrombin complex concentrate, activated prothrombin complex concentrate, and recombinant factor VIIa to reverse the effect of factor Xa inhibitors has been evaluated in animal studies, in vitro studies, and healthy volunteers, but not yet in randomized clinical studies...
May 16, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29764229/use-of-surgical-hemostatic-powder-for-ep-device-implantation-reduces-postoperative-rates-of-pocket-hematoma-and-infection
#5
Olga Reynbakh, Philippe Akhrass, Nektarios Souvaliotis, Chaithanya K Pamidimukala, Hasnun Nahar, Joseph Bastawrose, Pierre Boktor, Joshua E Aziz, Davendra Mehta, Emad F Aziz
BACKGROUND: Surgical site bleeding and infection are potential complications after EP device implantation procedures. To date, there is a wide variety of tools for management of intraoperative bleeding but it still remains unclear what methods are preferred. OBJECTIVE: The aim of our study is to compare the rate of complications in patients who underwent Cardiac Implantable Electronic devices (CIED) implantation utilizing Arista as a hemostatic agent to the rate of complications in those patients who underwent standard procedure protocol without Arista...
May 15, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29763772/graphene-kaolin-composite-sponge-for-rapid-and-riskless-hemostasis
#6
Yuping Liang, Congcong Xu, Guofeng Li, Tianchi Liu, Jun F Liang, Xing Wang
Kaolin is an effective and safe hemostatic agent for hemostasis. However, its ontic powder is difficult to use in actual practice. To develop a wieldy and powerful hemostat, composite strategy is usually a good choice. Herein, we developed a graphene-kaolin composite sponge (GKCS), synthesized with graphene oxide sheets, linker molecules and kaolin powders through a facile hydrothermal reaction. SEM observations support that GKCS has a porous structure, and EDS mapping further confirms that kaolin powders are embedded in graphene sheets...
May 8, 2018: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/29753076/bone-wax-in-neurosurgery-a-review
#7
REVIEW
Joe M Das
In this occasion of 125 years after the so-called "initial" use of bone wax (BW) by Sir Victor Horsley, a review of this age-old hemostatic agent deemed appropriate. The first use of BW for hemostasis is dated back to the 18th century when modeling or candle wax was used for hemostasis. Though the pioneers in the usage of BW in craniofacial surgeries were Belloq, Professor Khristian Khristianovich Salomon and François Magendie, its first successful use in neurosurgery was demonstrated by Henri Ferdinand Dolbeau in 1864, following the extirpation of a frontal osteoma...
May 9, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29749651/effects-of-immunosuppressive-agents-on-the-hemostatic-system-in-normal-dogs
#8
John M Thomason, Todd M Archer, Robert W Wills, Andrew J Mackin
BACKGROUND: In dogs, the effects of immunosuppressive medications on hemostasis are not well known. HYPOTHESIS/OBJECTIVES: The objective was to determine the effects of immunosuppressive medications on primary and secondary hemostasis. Our hypothesis was that cyclosporine and prednisone would increase markers of hypercoagulability and thromboxane synthesis, while azathioprine, mycophenolate mofetil, and leflunomide would have minimal effects on hemostasis. ANIMALS: Eight healthy dogs...
May 10, 2018: Journal of Veterinary Internal Medicine
https://www.readbyqxmd.com/read/29718871/neurological-symptoms-and-spinal-cord-embolism-caused-by-endoscopic-injection-sclerotherapy-for-esophageal-varices-a-case-report-and-literature-review
#9
Shiqian Liu, Nannan Wu, Mingkai Chen, Xi Zeng, Fang Wang, Qian She
RATIONALE: Spinal cord embolism is a rare complication of endoscopic injection sclerotherapy (EIS). PATIENT CONCERNS: We report a case of a 56-year-old man who presented neurological symptoms and spinal cord embolism caused by EIS on esophageal varices. Clinical signs and symptoms, laboratory tests, thoracic magnetic resonance imaging (MRI), and related treatment supported its diagnosis. DIAGNOSES:: spinal cord embolism. INTERVENTIONS: We stopped the hemostatic and anti-coagulation treatment, and switched to nerve nutrition, microcirculation, and hormone therapy, along with administering gastric mucosal protective agents...
May 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29696419/bleeding-related-to-dental-treatment-in-patients-taking-novel-oral-anticoagulants-noacs-a-retrospective-study
#10
Eun-Jung Kwak, Sangook Nam, Kyeong-Mee Park, Seo-Yul Kim, Jisun Huh, Wonse Park
OBJECTIVE: Several novel oral anticoagulants (NOACs) are currently prescribed for patients suffering from atrial fibrillation, pulmonary thromboembolism, and venous thrombosis. However, there is no clinical guideline for dental treatment in patients taking NOACs. This study investigated bleeding events related to various dental treatments. MATERIALS AND METHODS: This retrospective study included 120 patients (153 cases) who were prescribed NOACs and received dental procedures in the Department of Advanced General Dentistry at Yonsei University Dental Hospital from January 2014 to June 2017...
April 25, 2018: Clinical Oral Investigations
https://www.readbyqxmd.com/read/29693223/off-pump-hemostasis-for-left-ventricular-rupture-after-myocardial-infarction-with-hydrofit-%C3%A2-and-surgicel-%C3%A2
#11
Hikaru Ishii, Hidehito Endo, Hiroshi Tsuchiya, Yusuke Inaba, Katsunari Terakawa, Hiroshi Kubota
Left ventricular free wall rupture (LVFWR) is a catastrophic complication of myocardial infarction. In these cases, cardiopulmonary bypass (CPB) should be performed for left ventricular repair, but can impact hemodynamic stability. An 87-year-old man presented with acute shock. He was diagnosed with LVFWR after myocardial infarction. We describe a simple, effective, and reproducible technique to achieve hemostasis at the LVFWR site during emergency operation using Hydrofit® and Surgicel® surgical hemostatic agents...
April 24, 2018: General Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/29691259/transdermal-estradiol-for-the-management-of-refractory-uremic-bleeding
#12
Jimmy Gonzalez, Samantha Bryant, Evelyn R Hermes-DeSantis
PURPOSE: The efficacy and thrombogenicity of transdermal estradiol in the management of refractory uremic bleeding in adults are examined. SUMMARY: Platelet dysfunction from chronic kidney disease may induce uremic bleeding. This type of bleeding may involve the skin, oral and nasal mucosa, gingivae, respiratory system, and gastrointestinal or urinary tract. While the mainstay of treatment for uremic bleeding primarily involves dialysis and use of prohemostatic agents such as desmopressin and erythropoiesis-stimulating agents, certain patients may experience bleeding refractory to these interventions...
May 1, 2018: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/29684627/bioadhesives-for-internal-medical-applications-a-review
#13
REVIEW
Wenzhen Zhu, Yon Jin Chuah, Dong-An Wang
Bioadhesives such as tissue adhesives, hemostatic agents, and tissue sealants have gained increasing popularity in different areas of clinical operations during the last three decades. Bioadhesives can be categorized into internal and external ones according to their application conditions. External bioadhesives are generally applied in topical medications such as wound closure and epidermal grafting. Internal bioadhesives are mainly used in intracorporal conditions with direct contact to internal environment including tissues, organs and body fluids, such as chronic organ leak repair and bleeding complication reduction...
April 20, 2018: Acta Biomaterialia
https://www.readbyqxmd.com/read/29660028/reoperation-for-medulloblastoma-prior-to-adjuvant-therapy
#14
Prayash Patel, David Wallace, Frederick A Boop, Brandy Vaughn, Giles W Robinson, Amar Gajjar, Paul Klimo
BACKGROUND: Surgery remains an integral part of the treatment of medulloblastoma. We present our experience with repeat surgery for this tumor before initiation of adjuvant therapy. OBJECTIVE: To report what was found intraoperatively and where at time of second-look surgery and detail any postoperative events or readmissions within 90 days of surgery. METHODS: Two separate institutional databases were queried to identify patients who underwent repeat resection of suspected residual medulloblastoma from January 2003 to January 2017...
April 11, 2018: Neurosurgery
https://www.readbyqxmd.com/read/29658322/clinical-effectiveness-and-versatility-of-a-sealing-hemostatic-patch-hemopatch-in-multiple-surgical-specialties
#15
Kevin M Lewis, Shelly Ikeme, Tolu Olubunmi, Carl Erik Kuntze
Intraoperative surgical sealants and hemostatic agents have been shown to reduce postoperative complications, transfusions and hospital resource utilization. Despite availability of these agents, the incidence and burden of bleeding remains high and surgeons' requirements for hemostatic control continue to evolve. A burgeoning class of hemostatic agents are hemostatic patches, which offer package-to-patient readiness and direct application. In addition, hemostatic patches may provide tissue sealing capabilities...
April 16, 2018: Expert Review of Medical Devices
https://www.readbyqxmd.com/read/29645406/modified-clot-waveform-analysis-to-measure-plasma-coagulation-potential-in-the-presence-of-the-anti-factor-ixa-factor-x-bispecific-antibody-emicizumab
#16
Keiji Nogami, Tomoko Matsumoto, Yuka Tabuchi, Tetsuhiro Soeda, Nobuo Arai, Takehisa Kitazawa, Midori Shima
BACKGROUND: Emicizumab is an anti-factor (F)IXa/FX bispecific antibody that mimics FVIIIa cofactor function. Emicizumab does not require activation by thrombin and its effect on shortening activated partial prothrombin time (aPTT) is much greater relative to FVIII. The aPTT has limited utility, therefore, in hemophilia A patients (HA-pts) treated with emicizumab. AIM: To evaluate the global coagulation potential of emicizumab. METHODS: Clot waveform analysis (CWA) with prothrombin time (PT)/aPTT-mixed reagents was used to define hemostatic monitoring protocols in HA-pts...
April 12, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29643738/an-alternative-technique-in-the-control-of-massive-presacral-rectal-bleeding-fixation-of-gore-tex-%C3%A2-aortic-patch
#17
Mustafa Ozsoy, Zehra Ozsoy, Suleyman Sahin, Yüksel Arikan
The presacral venous system is located under the pelvic fascia covering the anterior of the sacrum and consists of two lateral sacral veins, middle sacral vein, and the veins that communicate them. The presacral venous system can be easily damaged and causes serious bleeding which is difficult to control and may cause intraoperative mortality. Its incidence varies between 3% and 9.4%. Although several methods have been tried to control presacral bleeding, the definitive method of treatment has not yet been identified...
January 2018: Nigerian Journal of Surgery: Official Publication of the Nigerian Surgical Research Society
https://www.readbyqxmd.com/read/29622877/prolonged-hemocoagulase-agkistrodon-halys-pallas-administration-induces-hypofibrinogenemia-in-patients-with-hematological-disorders-a-clinical-analysis-of-11-patients
#18
Xu Linglong, Wu Dijiong
Hemocoagulase Agkistrodon Halys Pallas, a well-established hemostatic agent used in China, has widespread applications in various conditions of bleeding and hemorrhages. Although it presents a low risk of vascular thrombosis, the agent can be easily tolerated and does not show any harmful effects, except allergy. However, long-term use of hemocoagulase may induce hypofibrinogenemia in some patients. Herein, we report 11 patients of prolonged administration of hemocoagulase Agkistrodon, with particular attention to the dynamic changes in their coagulation functions...
April 2018: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/29622331/postoperative-tonsillectomy-hemorrhage
#19
REVIEW
Jessica J Wall, Khoon-Yen Tay
Post-tonsillectomy hemorrhage represents a potentially life-threatening condition that occurs in up to 5% of pediatric patients. Minor bleeding often precedes severe hemorrhage. Patients with minor or self-resolving bleeding should be observed in the emergency department or admitted for monitoring. Patients with severe bleeding should be immediately assessed for airway and hemodynamic stability. Management of severe bleeding includes immediate surgical consultation or initiation of the transfer process to a center with surgical capabilities, direct pressure to the site of hemorrhage with or without the additional of a hemostatic agent, possible rapid sequence intubation, and management of hemodynamic instability with volume resuscitation...
May 2018: Emergency Medicine Clinics of North America
https://www.readbyqxmd.com/read/29605152/pharmacologic-hemostatic-agents-in-total-joint-arthroplasty-a-cost-effectiveness-analysis
#20
Dipak B Ramkumar, Niveditta Ramkumar, Stephanie J Tapp, Wayne E Moschetti
BACKGROUND: Total knee and hip arthroplasties can be associated with substantial blood loss, affecting morbidity and even mortality. Two pharmacological antifibrinolytics, ε-aminocaproic acid (EACA) and tranexamic acid (TXA) have been used to minimize perioperative blood loss, but both have associated morbidity. Given the added cost of these medications and the risks associated with then, a cost-effectiveness analysis was undertaken to ascertain the best strategy. METHODS: A cost-effectiveness model was constructed using the payoffs of cost (in United States dollars) and effectiveness (quality-adjusted life expectancy, in days)...
March 3, 2018: Journal of Arthroplasty
keyword
keyword
26052
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"